Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3027 vs Dupilumab in Moderate to Severe Atopic Dermatitis
NCT07754786Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 3 trial of IBI3027 in atopic dermatitis (AD), sponsored by Innovent Biologics. Started Sep 2026; status: recruiting.
02
Drugs
IBI3027
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07754786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754786.